Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft

Inclusion Criteria: * Multiple myeloma de novo. * Stage DS (Durie-Salmon) : III, II, I with at least 1 symptomatic bone lesion (confirmed by radiology). * Age \> 65 years * Indication for a first line treatment with induction, stem cell autologous graft and consolidation * Available documentation including cytogenetic and International Staging System (ISS) of the initial diagnosis before inclusion, * Effective contraceptive method for men with a partner of childbearing age during all the treatment period and within 6 months after the last cure * Affiliated to social security * Written informed consent * Willingness and ability to respect the visits and all the demands required by the study * Patient eligible to a high dose chemotherapy and fulfilling the following biological criteria : * Neutrophils ≥ 1,0 × 109/L * Platelets ≥ 75 ×109/L (platelets transfusions are not allowed within 3 days before inclusion) * Total bilirubin ≤ 1,5 × upper limit. * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit * Creatinin clearance \> 50 mL/min Exclusion Criteria: * Diagnosis and treatment for any other cancer within five years before inclusion or any diagnosis for any cancer. Patients with a skin cancer (except melanoma or carcinoma in situ) are not excluded in case of complete resection. * Central nervous system disease * Infection requiring an intravenous (IV) antibiotherapy or any severe infection within 14 days before inclusion * Diagnosis of any of the following diseases : Waldenström disease, POEMS (polyneuropathy, endocrinopathy, organomegaly, monoclonal gammapathy and skin lesions), plasma cell leukemia, primary amyloidosis, myelodysplastic syndrome or myeloproliferative disorder. * Uncontrolled cardiopathy including : uncontrolled hypertension, uncontrolled heart arrhythmia, nonsymptomatic congestive cardiac failure, unstable angina or myocardial infarction within 6 months before inclusion * Active infection with hepatitis B or C virus ; positive HIV serology * Any comorbidity or severe concomitant disease incompatible with the patient inclusion or interfering with the safety assessment of the study treatments. * Psychiatric history or any social condition limiting the patient compliance. * Documented allergy to any studied treatment or any of their components. * Disability to take oral treatments, inability or refusal to adhere to treatment constraints, or any digestive surgery interfering with oral absorption or treatment tolerance. * Any experimental treatment within 30 days prior to the administration of the first dose of the studied treatmentParticipation to another clinical trial * Prior participation to a clinical trial with elotuzumab, no matter the arm of treatment. * Administration of any pharmaceutical speciality acting against myeloma - such as systemic corticosteroids (\>10 mg of prednisone equivalent a day) or clarithromycin - within the month prior to the inclusion. In case of emergency, patients can receive dexamethasone (40mg/day, 4 consecutive days, maximum dose of 160mg) between screening and randomization